Towards Personalized Cancer Care: A Report of CRISPR-Cas9 Applications in Targeted Therapies and Precision Medicine
DOI:
https://doi.org/10.61919/jhrr.v4i2.1028Keywords:
Cancer, CRISPR-Cas9, clinical trials, gene therapy, genome editingAbstract
Background: Cancer resistance to chemotherapy arises from various genetic and epigenetic changes that promote malignant cell proliferation. The emergence of CRISPR-Cas9, a highly adaptable genome-editing tool, is revolutionizing cancer modeling by facilitating the precise generation of desired genetic mutations.
Objective: This study explores the efficacy of CRISPR-Cas9 in developing cellular and animal cancer models, correcting oncogenic mutations, and advancing cancer therapeutics through gene editing.
Methods: The CRISPR-Cas9 system was employed to introduce specific genetic alterations in cellular and animal models. These models were then used to simulate the complex interactions within tumors and to test the effectiveness of gene edits in mitigating cancer traits.
Results: Findings reveal that CRISPR-Cas9 enhanced the precision of anti-cancer treatments, with a significant reduction in tumor viability by up to 60% in treated models. Additionally, genetic corrections of mutated oncogenes achieved an efficiency of approximately 70%, underscoring the potential of CRISPR-Cas9 in targeted cancer therapy.
Conclusion: CRISPR-Cas9 has proven to be a powerful tool for cancer research, offering new avenues for the development of advanced therapeutic strategies. Its ability to modify genetic makeup efficiently holds promise for its integration into clinical settings, though challenges in safety and delivery remain.
Downloads
References
Knudson AG. Two genetic hits (more or less) to cancer. Nature Reviews Cancer. 2001;1(2):157-62.
Tucker L, Ali U, Zent R, Lannigan DA, Rathmell JC, Tiriveedhi V. Chronic High-Salt Diet Activates Tumor-Initiating Stem Cells Leading to Breast Cancer Proliferation. Cells. 2024;13(11):912.
Chen J, McKay RM, Parada LF. Malignant glioma: lessons from genomics, mouse models, and stem cells. Cell. 2012;149(1):36-47.
Sanyal S. Culture and assay systems used for 3D cell culture. Corning. 2014;9:1-18.
Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nature Reviews Cancer. 2008;8(8):592-603.
Bibbins-Domingo K, Grossman DC, Curry SJ. The US Preventive Services Task Force 2017 draft recommendation statement on screening for prostate cancer: an invitation to review and comment. Jama. 2017;317(19):1949-50.
Trafialek J, Kolanowski W. Dietary exposure to meat-related carcinogenic substances: is there a way to estimate the risk? International journal of food sciences and nutrition. 2014;65(6):774-80.
Seto M, Honma K, Nakagawa M. Diversity of genome profiles in malignant lymphoma. Cancer science. 2010;101(3):573-8.
Ali U, Tiriveedhi V. Critical role of defensins in respiratory viral infection induced breast cancer progression. Cancer Research. 2023;83(7_Supplement):341-.
Cyranoski D. CRISPR gene-editing tested in a person for the first time. Nature. 2016;539(7630).
Hille F, Charpentier E. CRISPR-Cas: biology, mechanisms and relevance. Philosophical transactions of the royal society B: biological sciences. 2016;371(1707):20150496.
Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD. Genome editing with engineered zinc finger nucleases. Nature Reviews Genetics. 2010;11(9):636-46.
Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339(6121):819-23.
Chang N, Sun C, Gao L, Zhu D, Xu X, Zhu X, et al. Genome editing with RNA-guided Cas9 nuclease in zebrafish embryos. Cell research. 2013;23(4):465-72.
van de Poll J. Future prospects of the applications of CRISPR/Cas9 in cancer research and therapy 2020.
Mojica FJ, Díez-Villaseñor Cs, García-Martínez J, Soria E. Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. Journal of molecular evolution. 2005;60:174-82.
Jansen R, Embden JDv, Gaastra W, Schouls LM. Identification of genes that are associated with DNA repeats in prokaryotes. Molecular microbiology. 2002;43(6):1565-75.
Carpenter JC, Lignani G. Gene editing and modulation: the holy grail for the genetic epilepsies? Neurotherapeutics. 2021;18(3):1515-23.
Hanahan D, Weinberg RA. The hallmarks of cancer. cell. 2000;100(1):57-70.
Gaj T, Gersbach CA, Barbas CF. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends in biotechnology. 2013;31(7):397-405.
Ali U, Vungarala S, Tiriveedhi V. Genomic Features of Homologous Recombination Deficiency in Breast Cancer: Impact on Testing and Immunotherapy. Genes. 2024;15(2):162.
Kaboli S, Babazada H. CRISPR mediated genome engineering and its application in industry. Current Issues in Molecular Biology. 2018;26(1):81-92.
Barrangou R, Marraffini LA. CRISPR-Cas systems: prokaryotes upgrade to adaptive immunity. Molecular cell. 2014;54(2):234-44.
Garneau JE, Dupuis M-È, Villion M, Romero DA, Barrangou R, Boyaval P, et al. The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature. 2010;468(7320):67-71.
Bilal A, Ahmad S, Tanvir F, Tariq M, Ramzan K, Saleem M, et al. PREDICTIVE MODELING OF N-ACETYL TRANSFERASE 2 SINGLE NUCLEOTIDE POLYMORPHISMS AND BREAST CANCER RISK USING IN-SILCO APPROACHES. THE JOURNAL OF MICROBIOLOGY AND MOLECULAR GENETICS. 2022;3(2):105-21.
Bilal A, Naveed N, Haider M. A brief note on cancer and its treatment. Occup Med Health Aff. 2021;9(7):1-3.
Sajjad MK, Bilal A, Iftikhar A, Awais M, Asif I, Shaheen F, et al. Examining the Association Between Pesticide Exposures and Chronic Diseases in Agricultural Workers. Remittances Review. 2024;9(2):2153-76.
Selvakumar SC, Preethi KA, Ross K, Tusubira D, Khan MWA, Mani P, et al. CRISPR/Cas9 and next generation sequencing in the personalized treatment of Cancer. Molecular Cancer. 2022;21(1):83.
Henry KS, Mackey HT. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline.
Qin M, Deng C, Wen L, Luo G, Meng Y. CRISPR-Cas and CRISPR-based screening system for precise gene editing and targeted cancer therapy. Journal of Translational Medicine. 2024;22(1):516.
Stefanoudakis D, Kathuria-Prakash N, Sun AW, Abel M, Drolen CE, Ashbaugh C, et al. The potential revolution of cancer treatment with CRISPR technology. Cancers. 2023;15(6):1813.
Morin RD, Arthur SE, Hodson DJ. Molecular profiling in diffuse large B‐cell lymphoma: why so many types of subtypes? British Journal of Haematology. 2022;196(4):814-29.
Allemailem KS, Alsahli MA, Almatroudi A, Alrumaihi F, Alkhaleefah FK, Rahmani AH, et al. Current updates of CRISPR/Cas9‐mediated genome editing and targeting within tumor cells: an innovative strategy of cancer management. Cancer Communications. 2022;42(12):1257-87.
Ray SK, Mukherjee S. Genome editing with CRISPR-Cas9: A budding biological contrivance for colorectal carcinoma research and its perspective in molecular medicine. Current Molecular Medicine. 2021;21(6):462-75.
Baltagiannis EG, Kyrochristos ID, Ziogas DE, Goussia A, Mitsis M, Roukos DH. From personalized to precision cancer medicine. Future Medicine; 2020. p. 245-50.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Ayesha Noor, Asif Bilal, Umer Ali
This work is licensed under a Creative Commons Attribution 4.0 International License.
